KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Debt Issuances: 2020-2022

  • Alnylam Pharmaceuticals' Long-Term Debt Issuances was N/A to -$777,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $966.1 million, marking a year-over-year change of. This contributed to the annual value of $1.0 billion for FY2022, which is N/A change from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Long-Term Debt Issuances of -$777,000 as of Q4 2022, which was down 100.08% from $1.0 billion recorded in Q3 2022.
  • In the past 5 years, Alnylam Pharmaceuticals' Long-Term Debt Issuances ranged from a high of $1.0 billion in Q3 2022 and a low of -$250.0 million during Q3 2021.
  • In the last 3 years, Alnylam Pharmaceuticals' Long-Term Debt Issuances had a median value of $99.6 million in 2020 and averaged $241.5 million.
  • Data for Alnylam Pharmaceuticals' Long-Term Debt Issuances shows a peak YoY spiked of 506.76% (in 2022) over the last 5 years.
  • Over the past 3 years, Alnylam Pharmaceuticals' Long-Term Debt Issuances (Quarterly) stood at $200.0 million in 2020, then reached -$250.0 million in 2021, then spiked by 506.76% to -$777,000 in 2022.
  • Its last three reported values are -$777,000 in Q4 2022, $1.0 billion for Q3 2022, and -$250.0 million during Q3 2021.